---
document_datetime: 2025-12-02 05:03:36
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/ajovy.html
document_name: ajovy.html
version: success
processing_time: 0.0966769
conversion_datetime: 2025-12-28 00:09:42.568688
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Ajovy

[RSS](/en/individual-human-medicine.xml/67183)

##### Authorised

This medicine is authorised for use in the European Union

fremanezumab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Ajovy](#news-on)
- [More information on Ajovy](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Ajovy is a medicine used to prevent migraine in adults who have migraines at least 4 days a month. The active substance contained in Ajovy is fremanezumab.

Expand section

Collapse section

## How is Ajovy used?

Ajovy is injected under the skin using a pre-filled syringe. Patients can inject the medicine themselves after being trained.

The recommended dose is either 225 mg every month or 675 mg every three months. For the 675 mg dose, three injections of 225 mg have to be injected one after another, each in a different place.

Ajovy can only be obtained with a prescription and treatment should be started by a doctor experienced in the diagnosis and treatment of migraine.

For more information about using Ajovy, see the package leaflet or contact your doctor or pharmacist.

## How does Ajovy work?

A chemical messenger called CGRP contributes to the development of migraine. Ajovy is a monoclonal antibody (a type of protein) designed to attach to CGRP and prevent it from binding to its target on the body's cells thereby helping to prevent migraines from occurring.

## What benefits of Ajovy have been shown in studies?

Ajovy was shown to reduce the number of days patients have moderate to severe headaches and migraines in 2 main studies.

In a study of 1,130 patients who had moderate to severe headaches 13 days a month on average, those treated with Ajovy had between 4 and 5 fewer days with moderate to severe headaches per month compared with 2 to 3 fewer days for patients on placebo (a dummy treatment), during the 12 week-study.

In a study with 875 patients who had migraines 9 days a month on average, those treated with Ajovy had between 3 and 4 fewer days with migraines per month compared with around 2 fewer days for patients on placebo, during the 12 week-study.

## What are the risks associated with Ajovy?

The most common side effects with Ajovy (which may affect more than 1 in 10 people) are reactions at the site of injection: pain, hardening (induration) and reddening of the skin (erythema).

For the full list of side effects and restrictions of Ajovy, see the package leaflet.

## Why is Ajovy authorised in the EU?

Ajovy can reduce the number of days patients have moderate to severe headaches and migraines. As most of the side effects are manageable and mild or moderate in severity, the European Medicines Agency decided that Ajovy's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Ajovy?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ajovy have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Ajovy are continuously monitored. Side effects reported with Ajovy are carefully evaluated and any necessary action taken to protect patients.

## Other information about Ajovy

Ajovy received a marketing authorisation valid throughout the EU on 28/03/2019.

Ajovy : EPAR - Medicine overview

Reference Number: EMA/107467/2019

English (EN) (96.07 KB - PDF)

**First published:** 17/04/2019

[View](/en/documents/overview/ajovy-epar-medicine-overview_en.pdf)

Ajovy : EPAR - Risk management plan

English (EN) (1.06 MB - PDF)

**First published:** 17/04/2019

**Last updated:** 17/05/2024

[View](/en/documents/rmp/ajovy-epar-risk-management-plan_en.pdf)

## Product information

Ajovy : EPAR - Product Information

English (EN) (1013.27 KB - PDF)

**First published:** 17/04/2019

**Last updated:** 04/04/2025

[View](/en/documents/product-information/ajovy-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-882)

български (BG) (1.2 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/bg/documents/product-information/ajovy-epar-product-information_bg.pdf)

español (ES) (1.09 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/es/documents/product-information/ajovy-epar-product-information_es.pdf)

čeština (CS) (1.16 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/cs/documents/product-information/ajovy-epar-product-information_cs.pdf)

dansk (DA) (1.14 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/da/documents/product-information/ajovy-epar-product-information_da.pdf)

Deutsch (DE) (1022.23 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/de/documents/product-information/ajovy-epar-product-information_de.pdf)

eesti keel (ET) (1.08 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/et/documents/product-information/ajovy-epar-product-information_et.pdf)

ελληνικά (EL) (1.29 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/el/documents/product-information/ajovy-epar-product-information_el.pdf)

français (FR) (1.11 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/fr/documents/product-information/ajovy-epar-product-information_fr.pdf)

hrvatski (HR) (1.16 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/hr/documents/product-information/ajovy-epar-product-information_hr.pdf)

íslenska (IS) (1.08 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/is/documents/product-information/ajovy-epar-product-information_is.pdf)

italiano (IT) (1.09 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/it/documents/product-information/ajovy-epar-product-information_it.pdf)

latviešu valoda (LV) (1.17 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/lv/documents/product-information/ajovy-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.23 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/lt/documents/product-information/ajovy-epar-product-information_lt.pdf)

magyar (HU) (1.18 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/hu/documents/product-information/ajovy-epar-product-information_hu.pdf)

Malti (MT) (1.37 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/mt/documents/product-information/ajovy-epar-product-information_mt.pdf)

Nederlands (NL) (1.04 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/nl/documents/product-information/ajovy-epar-product-information_nl.pdf)

norsk (NO) (1.11 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/no/documents/product-information/ajovy-epar-product-information_no.pdf)

polski (PL) (1.16 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/pl/documents/product-information/ajovy-epar-product-information_pl.pdf)

português (PT) (1.12 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/pt/documents/product-information/ajovy-epar-product-information_pt.pdf)

română (RO) (1.29 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/ro/documents/product-information/ajovy-epar-product-information_ro.pdf)

slovenčina (SK) (1.15 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/sk/documents/product-information/ajovy-epar-product-information_sk.pdf)

slovenščina (SL) (1.2 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/sl/documents/product-information/ajovy-epar-product-information_sl.pdf)

Suomi (FI) (1.07 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/fi/documents/product-information/ajovy-epar-product-information_fi.pdf)

svenska (SV) (1.09 MB - PDF)

**First published:**

17/04/2019

**Last updated:**

04/04/2025

[View](/sv/documents/product-information/ajovy-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0052 27/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Ajovy : EPAR - All Authorised presentations

English (EN) (155.7 KB - PDF)

**First published:** 17/04/2019

**Last updated:** 20/01/2020

[View](/en/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-776)

български (BG) (36.85 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/bg/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_bg.pdf)

español (ES) (12.41 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/es/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_es.pdf)

čeština (CS) (35.01 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/cs/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (12.5 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/da/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (12.37 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/de/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.46 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/et/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (36.07 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/el/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_el.pdf)

français (FR) (12.49 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/fr/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (21.35 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/hr/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (12.4 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/is/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_is.pdf)

italiano (IT) (16.25 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/it/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (36.5 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/lv/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (22.19 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/lt/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (30.39 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/hu/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (34.18 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/mt/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.3 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/nl/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (12.55 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/no/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_no.pdf)

polski (PL) (34.55 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/pl/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_pl.pdf)

português (PT) (12.81 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/pt/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.52 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/ro/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32.61 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/sk/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (21.38 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/sl/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (12.26 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/fi/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (12.56 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

20/01/2020

[View](/sv/documents/all-authorised-presentations/ajovy-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Ajovy Active substance fremanezumab International non-proprietary name (INN) or common name fremanezumab Therapeutic area (MeSH) Migraine Disorders Anatomical therapeutic chemical (ATC) code N02CD03

### Pharmacotherapeutic group

Calcitonin gene-related peptide (CGRP) antagonists

### Therapeutic indication

Ajovy is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

## Authorisation details

EMA product number EMEA/H/C/004833 Marketing authorisation holder

Teva GmbH

Graf-Arco-Straße 3

Opinion adopted 31/01/2019 Marketing authorisation issued 28/03/2019 Revision 13

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Ajovy : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (209.67 KB - PDF)

**First published:** 20/01/2020

**Last updated:** 04/04/2025

[View](/en/documents/procedural-steps-after/ajovy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Ajovy-H-C-PSUSA-00010758-202103 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/186908/2022

English (EN) (131.07 KB - PDF)

**First published:** 29/03/2022

[View](/en/documents/scientific-conclusion/ajovy-h-c-psusa-00010758-202103-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisation_en.pdf)

Ajovy- H-C-PSUSA-00010758-202003:  EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Adopted

Reference Number: EMA/332668/2020

English (EN) (139.47 KB - PDF)

**First published:** 06/08/2020

[View](/en/documents/scientific-conclusion/ajovy-h-c-psusa-00010758-202003-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Ajovy : EPAR - Public assessment report

Adopted

Reference Number: EMA/118499/2019

English (EN) (5.16 MB - PDF)

**First published:** 17/04/2019

[View](/en/documents/assessment-report/ajovy-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Ajovy

Adopted

Reference Number: EMA/CHMP/808036/2018

English (EN) (113.67 KB - PDF)

**First published:** 01/02/2019

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-ajovy_en.pdf)

#### News on Ajovy

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019) 01/02/2019

#### More information on Ajovy

- [EMEA-001877-PIP01-15-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001877-pip01-15-m04)
- [Pan European Prospective Observational Study of Fremanezumab effectiveness in patients with chronic or episodic migraine in the Real-World: PEARL study - post-authorisation study](https://catalogues.ema.europa.eu/study/35112)
- [Assessment of pregnancy outcomes in patients treated with Ajovy (fremanezumab): pregnancy registry (Teva migraine pregnancy registry) - post-authorisation study](https://catalogues.ema.europa.eu/study/40047)
- [Assessment of pregnancy outcomes in patients treated with Ajovy (fremanezumab): pregnancy database study - post-authorisation study](https://catalogues.ema.europa.eu/study/40050)
- [A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice Non-Interventional Phase 4 Study - post-authorisation study](https://catalogues.ema.europa.eu/study/42426)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 04/04/2025

## Share this page

[Back to top](#main-content)